W 1 - Heart
Contraindications to MRI (ht125039)
T Dill
Web only references
1. Schenck JF. Health effects and safety of static magnetic fields. In: Shellock FG, ed. Magnetic resonance procedures: health effects and safety. Boca Raton, Fla: CRC, 2001:1–30.
2. Zaremba LA. FDA guidance for magnetic resonance system safety and patient exposures: current status and future considerations. In: Shellock FG, ed. Magnetic resonance procedures: health effects and safety. Boca Raton, Fla: CRC, 2001:183–196.
3. Sawyer-Glover AM, Shellock FG. Pre-MRI procedure screening: recommendations and safety considerations for biomedical implants and devices. J Magn Reson Imaging 2000;12:510.
4. Evans JC, Smith ET, Nixon TE. A national survey of attitudes towards the use of MRI in patients known to have intracranial aneurysm clips. Brit J Radiol 2001;74:1118–1120.
5. Lee Pride G, Kowal J, Mendelsohn DB, et al. Safety of MR scanning in patients with nonferromagnetic aneurysm clips. J Magn Reson Imaging 2000;12:198–200.
6. Williamson MR, Espinosa MC, Boutin RD, et al. Metallic foreign bodies in the orbits of patients undergoing MR imaging: prevalence and value of radiography and CT before MR. Am J Roentgenol 1994;162:981–983.
7. Gieszl R, Williams KD, Drayer BP, et al. Magnetic resonance imaging and ferromagnetic bullets. Assoc Firearm and Tool Mark Examiners 1989;J21:595–604.
8. Teitelbaum GP, Yee CA, Van Horn DD, et al. Metallic ballistic fragments: MR imaging safety and artefacts. Radiology 1990;175:855–859.
9. American Society for Testing and Materials (ASTM) Designation F 2052. Standard test method for measurement of magnetically induced displacement force on passive implants in the magnetic resonance environment. In: Annual Book of ASTM Standards, Section 13, Medical Devices and Services, 01 Medical Devices; Emergency Medical Services. West Conshohocken, PA, 2002;13:1576–1580.
10. Syed MA, Carlson K, Murphy M, et al. Long-term safety of cardiac magnetic resonance imaging performed in the first few days after bare-metal stent implantation. J Magn Reson Imaging 2006;24:1056–1061.
11. Shellock FG, Forder JR. Drug eluting coronary stent: in vitro evaluation of magnetic resonance safety at 3 Tesla. J Cardiovasc Magn Reson 2005;7:415–419.
12. Shellock FG, Morisoli SM. Ex vivo evaluation of ferromagnetism, heating, and artifacts produced by heart valve prostheses exposed to a 1.5-T MR system. J Magn Reson Imaging 1994;4:756–758.
13. Shellock FG, Morisoli SM. Ex vivo evaluation of ferromagnetism and artifacts of cardiac occluders exposed to a 1.5-T MR system. J Magn Reson Imaging 1994;4:213–215.
14. Dempsey MF, Condon B, Hadley DM. Investigation of the factors responsible for burns during MRI. J Magn Reson Imaging 2001;13:627–631.
15. Kalin R, Stanton MS. Current clinical issues for MR scanning of pacemaker and defibrillator patients. Pacing Clin Electrophysiol 2005;28:326–8.
16. Stanton MS. Industry viewpoint: Medtronic: Pacemakers, ICDs, and MRI. Pacing Clin Electrophysiol 2005;28:265.
17. Levine PA. Industry viewpoint: St. Jude Medical: Pacemakers, ICDs and MRI. Pacing Clin Electrophysiol 2005;28:266–7.
18. Faris OP, Shein MJ. Government viewpoint: U.S. Food & Drug Administration: Pacemakers, ICDs and MRI. Pacing Clin Electrophysiol 2005;28:268–9.
19. Martin ET, Coman JA, Shellock FG, et al. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla. J Am Coll Cardiol 2004;43:1315–24.
20. Gimbel JR, Kanal E, Schwartz KM, et al. Outcome of magnetic resonance imaging (MRI) in selected patients with implantable cardioverter defibrillators (ICDs). Pacing Clin Electrophysiol 2005;28:270–3.
21. Nahrendorf M, Hiller KH, Hu K, et al. Pacing in high field cardiac magnetic resonance imaging. Pacing Clin Electrophysiol 2004;27:671–74.
22. Duru F, Luechinger R, Scheidegger MB, et al. Pacing in magnetic resonance imaging environment: clinical and technical considerations on compatibility. Eur Heart J 2001;22:113–124.
23. Hartnell GG, Spence L, Hughes LA, et al. Safety of MR imaging in patients who have retained metallic materials after cardiac surgery. Am J Roentgenol 1997;168:1157–1159.
24. Hess T, Stepanow B, Knopp MV. Safety of intrauterine contraceptive device during MR imaging. Eur Radiol 1996;6:66–68.
25. Teissl C, Kremser C, Hochmair ES, et al. Magnetic resonance imaging and cochlear implants: compatibility and safety aspects. Journal of Magnetic Resonance Imaging 1999;9:26–38.
26. Vahlensieck M. Tattoo-related cutaneous inflammation (burn grade I) in a mid-field MR scanner [Letter]. Eur Radiol 2000;10:97.
27. Colletti PM. Magnetic resonance procedures and pregnancy. In: Shellock FG, ed. Magnetic resonance procedures: health effects and safety. Boca Raton, Fla: CRC, 2001:149–182.
28. Shellock FG, Kanal E. Policies, guidelines, and recommendations for MR imaging safety and patient management. J Magn Reson Imaging 1991;1:97–101.
29. Rofsky NM, Pizzarello DJ, Weinreb JC, et al. Effect on fetal mouse development of exposure to MR imaging and gadopentate dimeglumine. J Magn Reson Imaging 1994;4:805–807.
30. Soltys RA. Summary of preclinical safety evaluation of gadoteridol injection. Invest Radiol 1992;27(suppl 1):S7–S11.
31. Kanal E, Borgstede JP, Barkovich AJ, et al. American College of Radiology White Paper on MR Safety: 2004 update and revisions. Am J Roentgenol 2004;182:1111–1114.
32. Morsetti A, Bussi S, Tirone P, et al. Toxicological safety evaluation of gadobenate dimeglumine 0,5 M solution for injection (Multihance), a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23(suppl 1):S207–S217.
33. Kubik-Huch RA, Gottstein-Aalame NM, Frenzel T, et al. Excretion of gadopentetate dimeglumine into human breast milk during lactation. Radiology 2000;216:555–558.
34. Saenz A, Mandal R, Kradin R, et al. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch 2006;449:389–391.
35. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta 1 expression in affected skin. Arthritis Rheum 2004;50:2660–2666.
36. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569–577.
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- type 1 w 2 enneagram
- heart medicine season 1 game
- 1 month before heart attack
- 4 is less than w and 1 is greater than w
- 1 or 2 374 374 1 0 0 0 1 168 1 1 default username and password
- 1 or 3 374 374 1 0 0 0 1 168 1 1 default username and password
- 1 or 2 711 711 1 0 0 0 1 168 1 1 default username and password
- 1 or 3 711 711 1 0 0 0 1 168 1 1 default username and password
- 1 or 2 693 693 1 0 0 0 1 168 1 1 default username and password
- 1 or 3 693 693 1 0 0 0 1 168 1 1 default username and password
- 1 or 2 593 593 1 0 0 0 1 or 2dvchrbu 168 1 1 default username and password
- 1 or 3 593 593 1 0 0 0 1 or 2dvchrbu 168 1 1 default username and password